MaxQ is excited to announce FDA Clearance for Accipio Ix V2.1. This newly released algorithm brings substantial clinical performance to the market with a sensitivity of 97% and specificity of 93%. In combination, MaxQ is releasing Accipio Ix V2.2. The underlying inference engine is the same as Accipio Ix V2.1 and therefore will have the same exceptional clinical performance to bring balance to acute ICH prioritization while reducing false positives.
In addition, Accipio Ix V2.2 will include an input image quality check to help confirm the input data meets the criteria defined in the user manual. Data identified to have substandard image quality resulting from motion, metal implants or fixtures, residual contrast, and/or incomplete skull anatomy will be flagged.
Based on clinical feedback from leading radiologists, exams flagged with potential input image quality deficiencies will still be processed through Accipio Ix V2.2 to ensure access of this critical ICH technology to the broadest population of patients. However, results generated with potentially substandard image quality will be tagged with a caution message regarding the quality of the input images so that the clinician has the information available to make an informed clinical interpretation.
MaxQ AI will support the complete ACCIPIO Clinical Suite with INSIGHT. It will support the Radiology Department, Emergency Room, Neuroradiology, and the Stroke teams with a fully automated solution. The ACCIPIO suite will provide tools for suspected positive ICH triage & prioritization (lx), slice-level annotation (Ax), lesion-level annotation (Ax Plus) lesion-level quantification (Ax Pro), triage of suspected positive and negative ICH (Dxg), and diagnostic rule out (Dx). The complete ACCIPIO solution for head trauma and stroke promises to:
• Greatly increase ICH detection and reduce missed ICHs through near real-time triage, annotation, and diagnostic rule-out – because every minute matters for head trauma and stroke patients.
• Potentially enhance clinical confidence, leading to mobilization of ischemic stroke neurosurgery teams, and the use of tPA.
• Provide the right care readied faster, improving quality to potentially avoid poor patient outcomes and to decrease costs and liability.
• Provide slice-level annotation, lesion level annotation, and quantification of lesion volume within suspected ICH.
• Provide automatic presence triage and automatic diagnostic ICH rule-out.
• Deployed through Major CT, AI ecosystem, and PACS channel partners; completely integrated, supported, and serviced from partners you trust.
• To address the total workflow needs of the reader. Not a single algorithm — an ecosystem designed to benefit the patient, care provider, and facility.
MaxQ AI Accipio Ix
MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide “smarter care” through intelligent imaging with actionable insights. We are committed to harnessing the power of artificial intelligence (AI) to raise the level of acute care in hospitals all around the world. We strive to deliver expert results to the physicians that save lives, improve care quality, and lower healthcare costs. Our mission is to reinvent patient diagnosis through artificial intelligence (AI), improved triaging and diagnostics processes, and reduction of avoidable medical errors and costs —all leading to better patient outcomes.
Watch how MaxQ AI’s Accipio Ix, which provides automatic, rapid, highly accurate identification and prioritization of suspected ICH, is integrated into the IBM Merge PACS AI-ready workflow platform.
The Merge PACS solution uses rules-based auto-routing to forward images to Accipio Ix. Accipio Ix then evaluates the non-contrast CT of the brain for hemorrhage and sends a screen capture image to Merge PACS indicating probable finding.
How AI is Being Used to Transform Radiology Practices with Dr. Ajay Choudhri. Automates manual tasks. Helps provide decision support. Helps detect subtle or complex patterns.
Zero clicks to ACCIPIO® results. Zero need to leave workflow. Zero stored PHI. Zero change to original series. No onsite IT integration required. Seamless from the Start™.
Improving the Workflow for Head Trauma and Stroke Care Patients.
Dr. Choudhri shares his experience with Accipio Ix for suspected positive ICH identification & prioritization. He answers questions such as: How Do You Select Your AI Solutions Vendor?
Zero Work. Zero Clicks. Completely Unobtrusive.
MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide “smarter care” through intelligent imaging with actionable insights. We are committed to harnessing the power of artificial intelligence (AI) to raise the level of acute care in hospitals all around the world. We strive to deliver expert results to the physicians that save lives, improve care quality, and lower healthcare costs.
We will improve potential diagnostic quality, confidence, speed, prioritization, and escalation to experts, extending the reach of department specialists.
This enables the possibility of better care in all market segments by bringing rapid clinical confidence to the reader while reducing variability across a care network.
The sheer volume of case-load, image counts, and decreasing physician availability demands a real solution to the burn-out of these front-line care providers.
With many community facilities having only emergency department support, along with no radiologist to read on nights and weekends, and a lack of sub-specialty neuroradiologists to escalate cases, there is often a lack of confidence of treating locally.
In this setting, the lack of confidence in identifying ICH can lead to unwarranted institutional transfer, withholding life-saving stroke care, and delayed action. This can have significant consequences for the patient, physician, and facility.
ACCIPIO provides projected expertise allowing the local facility, which makes the majority of care decisions, to determine the next, best treatment decision on treating there and now, or escalating further to additional resources.
In larger facilities, resources and escalation are not the primary issues. Effective use of these resources and a high-volume of patients are the areas of greatest need.
Having multiple head CT cases stacked in the queue, with no timely prioritization or triage for ICH, is common.
Key resources being used for “stoke mimics”, sent from the network community hospital, divert attention away from those in the greatest need. Over-escalating cases to neuroradiologists diverts attention from the patients that need it most. Mobile Stroke Units (MSU) can transmit early imaging data that helps guide patient routing and preparation of on-arrival resources.
We will provide enhanced escalation and intervention confidence, including mobilization of neurosurgery, thrombolysis, and thrombectomy resources for the right care readied faster.
The recipient of the Mobile Stroke Unit or Life-Flight unit should provide the needed information before they arrive to determine which is the best care facility.
Every patient deflected from stroke to wellness is a net benefit to the bottom line. On average, $150,000 per year in costs is required for stroke support/rehab of a patient*.
Payor/Providers are typically comprised of major metro centers with an academic “hub” and large, networked community facilities.
Compounded with the reality that many community facilities have only emergency department support, with no radiologist to read, or sub-specialty neuroradiologist to escalate the case for assistance – there is a large unmet need that can benefit from the “better together” result of ACCIPIO and the physician.